GlassScriptPhysician profile
Gang Bao
NPI 1922008598
$4,034.39
in general payments reported to CMS, 2019-2025
24 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.72 · 2020: $57.56 · 2021: $104 · 2022: $92.31 · 2023: $737 · 2024: $1,740 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,763.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $681.96 | 2023-2024 | Breztri, Airsupra, Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.27 | 2019-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $502.78 | 2023-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $423.55 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $325.76 | 2024-2025 | Lumryz |
| Harmony Biosciences LLC | $325.30 | 2020-2025 | Wakix |
| Pfizer INC. | $295.15 | 2023-2025 | |
| Novo Nordisk INC | $138.83 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Kvk-Tech, INC. | $131.84 | 2024 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2024 | Xarelto |
| Axsome Therapeutics, INC. | $117.37 | 2025 | Sunosi |
| Daiichi Sankyo INC. | $73.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.77 | 2025 | |
| 3b Medical, INC. | $38.26 | 2024-2025 | Luna |
| Janssen Biotech, INC. | $37.48 | 2024 | Simponi, Simponi Aria, Tremfya |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $33.26 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $27.33 | 2024-2025 | Prolastin-C Liquid |
| Abbvie INC. | $23.20 | 2020 | |
| Ironwood Pharmaceuticals, INC | $19.93 | 2020 | |
| Currax Pharmaceuticals LLC | $17.85 | 2024 | Contrave |
| Zoll Respicardia, INC. | $16.47 | 2025 | Remede System |
| Fisher & Paykel Healthcare INC | $15.79 | 2024 | Fisher & Paykel Healthcare |
| Merck Sharp & Dohme LLC | $13.10 | 2024 | Winrevair |
| Arbor Pharmaceuticals, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gang Bao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.